BACKGROUND: Prostate cancer (PCa) harbors a myriad of genomic and epigenetic defects. Cytosine methylation of CpG-rich promoter DNA is an important mechanism of epigenetic gene inactivation in PCa. There is considerable amount of data to suggest that DNA methylation-based biomarkers may be useful for the early detection and diagnosis of PCa. In addition, candidate genebased studies have shown an association between specific gene methylation and alterations and clinicopathologic indicators of poor prognosis in PCa. METHODS: To more comprehensively identify DNA methylation alterations in PCa initiation and progression, we examined the methylation status of 485 577 CpG sites from regions with a broad spectrum of CpG densities, interrogating both gene-associated and non-associated regions using the recently developed Illumina 450K methylation platform. RESULTS: In all, we selected 33 promoter-associated novel CpG sites that were differentially methylated in high-grade prostatic intraepithelial neoplasia and PCa in comparison with benign prostate tissue samples (false discovery rate-adjusted P-value o0.05; b-value X0.2; fold change 41.5). Of the 33 genes, hierarchical clustering analysis demonstrated BNC1, FZD1, RPL39L, SYN2, LMX1B, CXXC5, ZNF783 and CYB5R2 as top candidate novel genes that are frequently methylated and whose methylation was associated with inactivation of gene expression in PCa cell lines. Pathway analysis of the genes with altered methylation patterns identified the involvement of a cancer-related network of genes whose activity may be regulated by TP53, MYC, TNF, IL1 and 6, IFN-g and FOS in prostate pathogenesis. CONCLUSIONS: Our genome-wide methylation profile shows epigenetic dysregulation of important regulatory signals in prostate carcinogenesis.
INTRODUCTION
The progressive acquisition of both genetic and epigenetic defects is a major hallmark of human cancer, including prostate cancer (PCa). 1, 2 For human PCa, abundant evidence has accumulated to suggest that somatic epigenetic alterations may appear earlier during cancer development, as well as more commonly and consistently, than genetic changes. 3 Furthermore, epigenetic changes tend to arise in association with age 4 and/or in response to chronic or recurrent inflammation, leading to cell and tissue damage. 5 Among the aberrant epigenetic defects are changes in cytosine methylation patterns and in chromatin structure and organization, which are equivalent to genetic changes in effecting and maintaining neoplastic and malignant phenotypes. 6 There is considerable amount of data to suggest that DNA hypermethylation may be useful for the early detection and diagnosis of PCa. 7 The CpG residues, which serves as targets of DNA methylation, have an asymmetric distribution in mammalian genomes and are often found in small clusters called CpG islands (CGIs) . 8 Approximately 60% of all human gene promoters overlap with CGIs, 9 and accumulation of promoter DNA methylation is associated with gene silencing. 10 However, to date, only 115 genes are reported as methylation targets in PCa, 85 of which are listed in the Pubmeth database (http://www. pubmeth.org). 11 Methodologies that have been used to analyze DNA methylation changes in PCa have varied from a few CpG sites 12 to assessing several thousand genomic regions with a the CGI array. 13 The sodium bisulfite modification approach for distinguishing between methylated and unmethylated DNA has been used in combination with methylation-sensitive (for example, R. HpaII) and -specific (for example, R. McrBCI) restriction enzymes, and/or affinity reagents specific for methylated DNA, such as the anti-5meC antibody or recombinant methyl-binding polypeptides. 14, 15 However, these techniques require a high level of specialization and are still expensive and time-consuming. The advent of DNA methylation microarrays with a user-friendly component is now available. Among them is the recently developed Infunium human methylation array (Illumina Infinium Human Methylation 450 BeadChip) that offers high-throughput method for quantitatively assessing methylation across the genome and has been validated for both biology and function in colorectal cancer. 16 The goal of the present study is to apply this technique to identify new sites of methylation that can be correlated with the presence of PCa or result in silencing of genes previously not identified but functionally important for the initiation of PCa.
MATERIALS AND METHODS

Prostate cell lines
The immortalized normal prostate epithelial cell line RWPE1 and the human PCa cell lines PC3, DU145 and LNCaP, and BPH cell line were obtained from the American Type Culture Collection (Manassas, VA, USA). The immortalized normal prostate epithelial cell line pNT1A was obtained from the European Collection of Cell Culture (Salisbury, UK). The above cell lines were all derived from European American (EA) patient samples. The androgen-dependent PCa cell lines, E00D6AA, and androgenindependent cell line, MDA-PCa2b, were derived from African American (AA) PCa patients and obtained from ATCC. All cell lines are maintained in RPMI supplemented with fetal bovine serum (10%) (Invitrogen, Carlsbad, CA, USA) unless stated otherwise. The androgen-dependent PCa cell lines HPC1L and HPC8L were derived from anAA PCa patient at the Howard University under the Howard University Institutional Review Board approval. The HPC1L and HPC8L cell lines are positive for androgen receptor, PSA and epithelial membrane antigen. The HPC1L and HPC8L cells were maintained in RPMI supplemented with cholera toxin (2.5 ng ml À 1 ), epidermal growth factor (10 ng ml À 1 ), insulin (5 ng ml À 1 ), hydrocortisone (100 pg ml 
Human prostate tissue samples
Normal (benign prostate tissues, NL), high-grade prostatic intraepithelial neoplasia (HGPIN) and PCa (Gleason score 6-8) tissues, as well as pairs of matched NL and PCa tissues (same patient samples) were obtained with informed consent from the Baylor College SPORE tissue bank. The pathological status was confirmed by hematoxylin and eosin staining, and the cancer samples had a tumor cell percentage of 70-100% with Gleason scores of 6-8. All individual samples were obtained from EA patients (age 45-67 years old) who were either organ donors or had undergone radical prostatectomy.
Genome-wide methylation analysis
High molecular weight genomic DNA (0.5 mg) was bisulfite converted using the EZ DNA Methylation Gold kit (Zymo Research, Irvine, CA, USA). DNA was then whole-genome-amplified, enzymatically fragmented, precipitated, resuspended and hybridized at 48 o C for 16 h to an array containing 485 577 locus-specific oligonucleotide primers (Illumina, San Diego, CA, USA). The probes were recognized at 20 216 transcripts, potential transcripts or isolated CGIs. After hybridization, the cytosine or thymine nucleotides were detected by fluorescent single-base primer extension using an Illumina Hi Scan SQ scanner. Initial array results were visualized using Illumina Genome Studio (Version 2011). The methylation score for each CpG site is represented as a b-value. The b-value is a continuous variable ranging between 0 and 1, representing the ratio of the intensity of the methylated-probe signal to the total locus signal intensity. A b-value of 0 corresponds to no methylation, whereas a value of 1 corresponds to 100% methylation at the specific CpG site measured. P-values were calculated to identify failed probes as per Illumina's recommendations and no arrays exceeded our quality threshold of 45% failed probes. In addition, we removed CpG sites on the X and Y chromosome [17] [18] [19] and removed CpG sites from the analysis that contained a single-nucleotide polymorphism or a single-nucleotide polymorphism within 10 base pairs of the methylation probe 17 according to dpSNP132. We only focused on CpG sites within known CGIs from the UCSC database (n ¼ 200 419 CpG sites). The sites in the UCSC database were discovered using a modified method from Gardiner-Garden and Frommer. 20 Raw data were normalized using Illumina's control probe scaling procedure 17 and background subtracted.
The b-values were imported into Partek Genomics Suite (version 6.6; Partek, St Louis, MO, USA) and underwent a logit transformation (M-value). 21 The M-value is calculated as the log2 ratio of the intensities of the methylation probes versus unmethylated probe. The problem of heteroscedasticity in the high and low ranges of methylation (o0.2 and X0.8) is resolved with the transformation of the b-value to M-value.
In addition, we removed noise from our analysis by examining only CGIs with a b-value of X0.1. The data were analyzed using a Student's t-test between NL, HGPIN and PCa. The M-value score was treated as a continuous variable that is the response for the analysis of variance model. An false discovery rate correction was implemented, but none of the identified CGIs were significant. Therefore, we validated the results with pyrosequencing.
These b-values were used to calculate a ratio of relative methylation between samples, with higher values corresponding to greater levels of methylation (hypermethylation) in tumor tissue relative to normal. Hypomethylation is defined as methylation in normal prostate samples but undermethylated in tumor samples. The CpG methylation differences were considered significant above a cut-off P-value o10 -3 and 0.2-fold change in the b-value, unless specifically indicated otherwise. Unsupervised hierarchical clustering analysis of the most variable b-values was done with a false discovery rate-adjusted P-value o0.05as significant. All other computations and statistical analyses were performed using Partek Genome Studio.
Pyrosequencing
High-molecular-weight genomic DNA was bisulfite converted using Epitect Bisulfite kit (Qiagen, Valencia, CA, USA). Pyrosequencing was done using the PSQ HS96 Gold SNP Reagents on a PSQ 96HS machine (Qiagen, Gaithersburg, MD, USA). Primers were designed in-house or commercially available PyroMark CpG assays consisting of PCR and sequencing primers were used according to the manufacturer's protocol (Qiagen). Epitect ready-to-use, completely methylated and bisulfite-converted human control DNA was used as a positive control and unmethylated and bisulfite-converted human control DNA was used as a negative control. Each bisulfite PCR and pyrosequencing reaction was done at least twice.
Gene expression
Total RNA extracted from cells and prostate tissues using TRIzoL Reagent (Invitrogen) was used in cDNA synthesis using Invitrogen SuperScript first strand synthesis system for reverse transcriptase-PCR and according to the manufacturer's protocol (primers used are listed in Table 3 ). Either SYBR green or TaqMan assay (designed for BNC1, FZD1, CYB5R2 and SYN2) were used to quantitatively measure mRNA expression. Real-time PCR was carried out in a Bio-Rad iCycler real-time thermal cycler (Biorad, Hercules, CA, USA) as described previously, 22 and incorporating optimized PCR reaction conditions for each gene. The threshold cycle (C t ) in the PCR cycle at which fluorescence exceeds background was then converted to copy number based on a cDNA standard curve generated. Each experiment was carried out in duplicate.
Treatment with 5-aza-2 0 -deoxycytidine and/or trichostatin A The pNT1A, DU145, PC3 and LNCaP cells were seeded at 5 Â 10 5 cells per 100-mm tissue culture dish. After 24 h of incubation, the culture media was changed to a media containing 5 0 -aza-dC (5-aza-2 0 -deoxycytidine; 5 mM) for 72 h and/or trichostatin A (TSA; 250 nM) for an additional 24 h. Total RNA extracted from cells using TRIzol Reagent (Invitrogen) was first used in first strand DNA (cDNA) synthesis using Invitrogen Super-Script first-strand synthesis and then used in real-time quantitative PCR as previously described. 23 Mock-treated cells were cultured similarly. Three independent experiments were carried out for each analysis.
Pathway analysis
Biological functional categorization and pathway construction were performed using the Ingenuity Pathway Analysis software tool produced by Ingenuity systems. Ingenuity Pathway Analysis utilizes an extensive database of functional interactions, which are drawn from peer-reviewed publications and manually maintained. 24 
Statistical Analyses
The methylation index at each gene promoter and for each sample was calculated as the average value of mC/ (mC þ C) for all examined CpG sites in the gene and was expressed as the percentage of methylation. Data analysis was done using either Prism 4 software (GraphPad Software, La Jolla, CA, USA) or SPSS for Windows (version 13.0, SPSS, Armonk, NY, USA). Comparison of grouped samples b was done using analysis of variance for NL, PCa and HGPIN, and age as categorical variables with fixed effects. For each gene, the frequencies of methylated and unmethylated cases were analyzed using rank-sum Mann-Whitney's U-test to compare each group in pair-wise fashion. Resulting P-values were adjusted for multiple comparisons using the Bonferroni-adjusted Mann-Whitney's U-test. The nonadjusted statisitcal level of significance of Po0.05 corresponds to a Bonferroni-adjusted statistical significance of Po0.0167.
RESULTS
450K DNA methylation analysis of genomic DNA from prostate tissues In order to find CpG sites that are differentially methylated in NL, HGPIN and PCa tissue samples, we used the Illumina Infinium platform to conduct a genome-wide large-scale analysis of DNA methylation changes. For our analysis, we included six NL, seven HGPIN and six PCa tissue samples from EA men who are either organ donors or had undergone radical prostatectomy. Unsupervised hierarchical clustering analysis of all samples ( Figure 1 ) shows heterogeneity in individual prostate tissue samples. However, most normal prostate tissue samples (five out of six cases) clustered together, whereas most HGPIN and PCa cases generally clustered together. We separated the methylation arrary data into three subsets. The first subset consisted of six PCa samples compared with six NL samples, the second subset consisted of seven HGPIN samples compared with six NL samples and the third subset consisted of six PCa samples compared with seven HGPIN samples. Table 1 shows the results of the most significant differentially methylated genes identified in our analysis. We observed 1317 CpG sites to be hypermethylated and 44 CpG sites to be hypomethylated in PCa tissues when compared with normal prostate tissues. The HGPIN samples showed 167 CpG sites to be hypermethylated and 312 CpGs to be hypomethylated when compared with the normal prostate tissues. In addition, we observed 138 hypermethylated CpG sites and 7 hypomethylated CpG sites when we compared PCa tissues with HGPIN. As expected, CpG sites corresponding to genes that were previously shown to be hypermethylated in PCa were also hypermethylated in our samples, including GSTPI, RASSF1A and NKX2-5.
4,25 Our analysis shows high frequency of hypermethylation in PCa tissues in comparison with normal prostate tissues. Our observation of more hypomethylation than hypermethylation sites from the array data in HGPIN versus normal prostate is consistent with other published studies that reported genomewide DNA hypomethylation as prevalent as hypermethylation, 26, 27 with substantial DNA hypomethylation in genes of cancer cells compared with their normal counterparts. 28 However, differences in the hypermethylation and hypomethylation frequencies observed in PCa versus normal prostate tissues when compared with HGPIN versus normal prostate tissues may reflect the random variability in tissue composition or random nature of affected methylation sequence.
Overall, several of these CpG sites are located in the genomic regions that are not associated with gene promoter loci (data not shown). Previous reports indicate that the distribution of the CpG content in the human genome is estimated to be 30.9% in CGIs, 23% in CpG shores, 9.7% in CpG shelves and 36.3% are isolated CpGs in the genome defined as 'open sea'. 16 We excluded genes without CGIs in the promoter and imprinted genes, 29 and focused on CpG-methylated sites in proximal promoters defined as the sum of CpG sites located within 200 bp downstream or 1500 bp upstream of the transcription start site in order to assess the effects of promoter methylation on gene expression. From a functional genome distribution Figure 1 . Hierarchical cluster analysis of methylation findings from the microarray data. DNA methylation hierarchical clustering shows high within-sample group similarity and between-samples heterogeneity. These analyses were done using Partek genome studio software with 450 gene probes showing greatest variability across all samples. CpG methylation differences were considered significant above a cut-off P-value o10 -3 and 0.2-fold change in the b-value. The scale is based on b-value (M-value; as determined by Partek Genome Studio) for methylation score. HGPIN, high-grade prostatic intraepithelial neoplasia. standpoint, these proximal promoters account for 41% of the CpGs in the human genome. 16 Using this approach, we selected the top 33 novel genes that are common and differentially methylated in PCa versus NL and HGPIN versus NL prostate tissues (Table 2 ).
Pyrosequencing analysis of novel methylated genes
To confirm the accuracy of the Illumina methylation array, we used pyrosequencing to analyze the methylation status of the 33 novel genes in normal and PCa cell lines derived from both EA and AA men. For pyrosequencing, we used both commercially designed primers from Qiagen and primers that were designed in-house (see Table 3 for primers detail). A heat map hierarchical cluster analysis for the methylation status in the prostate cell lines is shown in Figure 2 . The results demonstrated that the 33 novel genes were methylated in at least 1 PCa cell line with higher methylation frequency for the majority of the genes analyzed in the PCa cell lines when compared with the primary immortalized normal prostate cell lines. Interestingly, we observed higher methylation frequency in the PCa cell lines that were derived from the AA when compared with EA PCa cell lines. This observation is consistent with a previously published study, 30 where we reported significantly higher methylation frequency in human prostate tissues samples from AA patients in comparison with EA patients, clearly demonstrating that differential methylation patterns in AA and EA men may result in altered patterns of gene expression and contribute to PCa disparity. Overall, we identified BNC1, FZD1, RPL39L, SYN2, LMX1B, CXXC5, ZNF783 and CYB5R2 as top candidate genes that are frequently hypermethylated in PCa cell lines.
Validation of methylated genes in PCa progression
To determine whether the genes that were hypermethylated in PCa cell lines were hypermethylated in a cancer-specific manner, we analyzed the methylation status of the 8 top novel genes in the samples used in the array analysis, and additional 23 NL and 17 PCa that were available. The methylation frequency and mean are shown in Figure 3a . In general, statistically significant differences (Po0.05) in the methylation frequencies were noted in PCa samples in comparison with the benign prostate tissues for BNC1, FZD1, SYN2, ZNF783 and CYB5R2 genes. Significant differences were also noted for HGPIN samples in comparison with benign prostate tissues for SYN2 and CYB5R2 genes. However, no significant differences in the methylation frequency were noted for the HGPIN tissue samples in comparison with the PCa tissues. Our data clearly demonstrate that the methylation levels of these novel genes can distinguish between benign and HGPIN or PCa tissues. However, we need a larger sample size to confirm these preliminary data.
To investigate whether methylation is associated with gene expression in PCa tissues, we performed expression analysis by quantitative reverse transcriptase-PCR for BNC1 and CYB5R2.
The results presented in Figure 3b showed a significantly higher level of gene expression for BNC1 (Po0.0001) and CYB5R2 (P ¼ 0.0004) in the matched NL when compared with the PCa tissues. Our data suggest an inverse association between DNA methylation and gene expression for BNC1 and CYBR52 (cytochrome b(5) reductase 2). We observed that in cancer samples that showed higher methylation, this was associated with low levels of gene expression, whereas the normal prostate Abbreviation: U, universal primer sequence. Primer sequences above used in the pyrosequencing analysis were designed in-house. U represents universal primer sequence-5 0 -GGGACACCGCT GATCGTTTA-3 0 .
DNA methylation biomarkers and PCa and HGPIN JM Devaney et al samples had lower methylation and higher gene expression level to indicate that methylation leads to some loss of gene expression.
Gene expression and induction after 5-aza-dC treatment in prostate cell lines To confirm that hypermethylation affects gene expression, we tested the hypothesis that pharmacological modulation of methylation can reactive gene expression, 31 PCa cell lines were treated with the demethylating agent 5 0 -Aza-dC with or without the histone deacetylase inhibitor, TSA. Gene expression was analyzed by quantitative reverse transcriptase-PCR using untreated and treated cells to assess whether promoter CGI hypermethylation was closely associated with gene expression in the newly identified cancer-specific methylated genes (Figure 4) . Treatment with 5 0 -Aza-dC, an inhibitor of the DNA methyltransferase, 31 caused over twofold increase in mRNA transcript expression levels for BNC1, CYB5R2 and FZD1, and a modest increase in the mRNA transcript level for SYN2. Previous reports have suggested that histone deacetylase cooperates with methyl-binding proteins at hypermethylation CGIs to repress transcription, 32, 33 and Cameron et al. 34 have reported that methylation-induced transcriptional repression could be overcome with a combination of 5 0 Aza-dC and TSA. We have found that treatment with TSA also modestly increased the mRNA transcript levels for BNC1 and FZD1; however, the combined 5 0 Aza-dC and TSA treatment synergistically increased the mRNA transcripts for all genes tested in both the androgen-dependent (LNCaP) and the androgen-independent (PC3) cell lines. The results indicate that epigenetic mechanisms, including DNA methylation, are likely involved in the reduced expression of BNC1, CYB5R2, FZD1 and SYN2.
DISCUSSION
With advancements in microarray technology, the number of genes found to be hypermethylated in PCa in a cancer-specific manner is expected to increase exponentially, leading to a better understanding of epigenetic modulation of tumor-related genes in prostate carcinogenesis. To identify novel methylated genes associated with PCa progression, we have applied the Illumina Infinium human genome-wide DNA methylation array that consists of 485 577 CpG sites using prostate tissue samples corresponding to benign, HGPIN and PCa tissues.
We present the identification of several novel genes demonstrating cancer-specific methylation in PCa through the use of Infinium arrays. The fidelity of the Illumina Infinium array was confirmed using pyrosequencing for genes selected according to our criteria described above. As a result, 33 novel promoter-associated CpG sites were observed to be differentially methylated in HGPIN and PCa in the DNA array analysis. Most of the genes identified through our arrary analysis have either never been shown to be methylated in PCa or in other cancer types. Previously reported methylated genes in PCa, such as GSTPI, RASSF1A and NKX2-5, all showed evidence of methylation based on fold changes and statistical significance. However, the stringency of the statistical analyses that we performed may have excluded these genes within our top genes of the cancer/ reference data set. The methylation status of all 33 genes were validated by pyrosequencing in PCa cell lines, with at least two out of the eight PCa cell lines showing hypermethylation in comparison with the immortalized primary epithelial prostate cell lines (RWPE1) for these genes. Eight out of the 33 genes were selected for methylation validation in human prostate tissues, because they were frequently hypermethylated in the PCa cell lines. The promoter-associated CpG sites for BNC1, FZD1, SYN2, ZNF783 and CYB5R2 genes demonstrated significant differences in methylation level in HGPIN and PCa when compared with the NL prostate tissues; therefore, we tested whether pharmacological modulation can reactivate gene expression, which would be indicative of methylation having a role in gene expression (we did not investigate ZNF783, because it should hypermethylation even in the NL samples). Treatment of PCa cell lines with 5-aza-dc and TSA drugs induced gene re-expression; therefore, these genes are considered to be repressed by DNA hypermethylation in their promoter CGI, suggesting they can be potentially explored as novel markers for disease identification. These novel genes have diverse roles in normal and PCa pathogenesis, which underscore the myriad way these epigenetic aberrations may contribute to PCa disease etiology and/or progression. For instance, BNC1 belongs to the basonuclin gene family, which encodes for zinc finger proteins mainly expressed in the epidermis, hair follicles and the germ cells of the testis and ovary. 35 The BNC1 protein is an unusual transcription factor that interacts with a subset of promoters of genes that are transcribed by both RNA polymerase-I and -II, and has roles in maintaining ribosomal biogenesis and the proliferative potential of immature epithelial cells. 36 Methylation of BNC1 has previously been reported in renal cell carcinoma 37 and in chronic lymphocytic leukemia. 38 Here we describe the methylation and silencing of BNC1 in PCa tissues. Our observation supports previous reports of frequent methylation of BNC1 across common epithelial cancers. Similarly, Wnt/Frizzleds (FZD; including FZD1) signaling is known to have a key role in development, tissue-specific stem cell maintenance and tumorigenesis, particularly through the canonical pathway involving stabilization of b-catenin. 39 Studies in mouse models have suggested a role for Wnt/FZD signaling in promoting tumorigenesis. 39 Here we describe the methylation of FZD1 in PCa. One group has previously reported the age-dependent methylation of FZD1 by whole human genome analysis. 40 . Other groups have reported aberrant expression of FZD1 in colon cancer, 41 breast cancer cells 42 and in neuroblastoma, 43 suggesting a potential role for FZD1 in processes associated with tumor invasion. However, some groups have reported increased expression of FZDs (including FZD1) in cancer tissues. [41] [42] [43] Although it is not clear why FZD1 expression may parallel DNA methylation changes, increased DNA methylation in the gene bodies of expressed genes has been reported and may have a role in the gene transcription 44, 45 On the other hand, loss of the secreted Fzd-related protein 1 and 2 (SFRP1 and -2) expression by hypermethylation has been reported in human cancers, including PCa 46 and breast cancer tissues 47 to suggest that hypermethylation of SFRPs may be a common phenomenon in tumorigenesis. Another novel gene that we have identified is CYB5R2 gene, which belongs to the family of drug-metabolizing enzymes that are responsible for the activation, inactivation and detoxification of many chemotherapeutic agents, and deficiencies in these enzymes may result in bioavailability and disposition of these agents. 48 Several studies have shown polymorphisms in genes encoding these drug-metabolizing enzymes and association with response to cancer treatment. 49 The most important polymorphisms shown to influence survival after cancer treatment are polymorphisms in the genes encoding the phase II detoxification enzymes glutathione-S-transferase (including glutathione S-transferase pi; GSTP1). In PCa, polymorphisms do not appear to be associated with increased PCa risk, but promoter methylation of GSTP1 has been reported as frequent alteration in the disease etiology and progression. 50 To our knowledge, this is the first report to indicate that CYB5R2 is also dysregulated in PCa by DNA methylation. The sensitivity of BNC1, FZD1, SYN2 and CYB5R2 methylation were similar to other well-known methylated genes, including GSTP1, RARb2 and RASSF1A, which we have tested using the pyrosequencing technique. 4 Our analysis also investigated methylation differences in HGPIN in comparison with PCa tissues. Although HGPIN displays intermediate methylation frequencies between benign prostate tissues and PCa for several genes that is consistent with previous reports, 51, 52 we did not observe any significant differences in the methylation frequencies for the HGPIN tissues in comparison with the PCa tissues. Previous reports have demonstrated significant differences in the methylation frequencies for several genes, including RARb2, RASSF1A, GSTP1 in HGPIN in comparison with PCa. 53, 54 Our result is probably due to the smaller sample size used in the current studies and perhaps a narrow spectrum of pathologic tumor stages that did not allow for a more powerful statistical analysis. In addition, one study that surveyed a panel of nine gene promoters only found four genes with methylation levels that differed significantly between HGPIN and PCa, 53 suggesting that hypermethylation of specific gene promoters maybe associated with advanced prostate tumor grade and stage.
In summary, we have identified 33 novel cancer-specific methylated markers for PCa using Illumina Infinium array and pyrosequencing. Of these BNC1, FZD1, SYN2, ZNF783 and CYB5R2 were frequently hypermethylated in a PCa tissue-specific manner, and their promoter hypermethylation was correlated with inactivation of gene expression in cell lines. Differential methylation has significant potential for clinical use as a biomarker, as methylation is stable in formalin-fixed parafin-embedded tissues and can be detected in very small numbers of cells using PCR-based techniques. Further studies will look into the implications of these newly identified DNA methylation markers for patient outcome in a large scale study of PCa samples. ), or a combination of the two drugs. This cell line had high methylation levels for the genes tested and all had very low levels of expression at baseline. The gene expression was determined by quantitative reverse transcriptase-PCR and expressed relative to b-actin to correct for variation in the amounts of reverse-transcribed RNA. The data are representative of three independent experiments. The fold change in gene expression level was calculated relative to the control (untreated cells) that was set at an arbitrary unit of 1.
